{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T15:07:20Z","timestamp":1768316840668,"version":"3.49.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journalofclinicalvirology.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.jcv.2017.04.012","type":"journal-article","created":{"date-parts":[[2017,4,23]],"date-time":"2017-04-23T03:31:33Z","timestamp":1492918293000},"page":"7-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["HIV-1 integrase inhibitor resistance among treatment na\u00efve patients in the West of Scotland"],"prefix":"10.1016","volume":"92","author":[{"given":"A.","family":"Bradley-Stewart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Urcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"MacLean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Aitken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Gunson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9180","key":"10.1016\/j.jcv.2017.04.012_bib0005","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(98)12262-6","article-title":"Transmission of antiretroviral-drug-resistant HIV-1 variants","volume":"354","author":"Yerly","year":"1999","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jcv.2017.04.012_bib0010","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3851\/IMP1750","article-title":"Transmitted resistance to HIV integrase strand-transfer inhibitors: right on schedule","volume":"16","author":"Hurt","year":"2011","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.jcv.2017.04.012_bib0015","doi-asserted-by":"crossref","first-page":"e94495","DOI":"10.1371\/journal.pone.0094495","article-title":"Patterns of transmitted HIV drug resistance in Europe vary by risk group","volume":"9","author":"Frentz","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1016\/j.jcv.2017.04.012_bib0020","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1473-3099(11)70032-9","article-title":"Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study","volume":"11","author":"Wittkop","year":"2011","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.jcv.2017.04.012_bib0025","article-title":"Recent trends and patterns in HIV-1 transmitted drug resistance in the United Kingdom","author":"Tostevin","year":"2016","journal-title":"HIV Med."},{"key":"10.1016\/j.jcv.2017.04.012_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-1293.2011.00971.x","article-title":"BHIVA guidelines for the routine investigation and monitoring of adult HIV-1 infected individuals 2011","volume":"13","year":"2012","journal-title":"HIV Med."},{"key":"10.1016\/j.jcv.2017.04.012_bib0035","unstructured":"BHIVA guidelines for the treatment of HIV-1 positive adults with antiretroviral therapy 2015 (2016 interim update). http:\/\/www.bhiva.org\/documents\/Guidelines\/Treatment\/2016\/treatment-guidelines-2016-interim-update.pdf (accessed 15.08.16)."},{"issue":"3","key":"10.1016\/j.jcv.2017.04.012_bib0040","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/cid\/cit697","article-title":"Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009\u20132012","volume":"58","author":"Hurt","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jcv.2017.04.012_bib0045","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1093\/jac\/dku535","article-title":"Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients","volume":"70","author":"Fourati","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"issue":"11","key":"10.1016\/j.jcv.2017.04.012_bib0050","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1093\/jac\/dkv243","article-title":"Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades","volume":"70","author":"Doyle","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"issue":"2","key":"10.1016\/j.jcv.2017.04.012_bib0055","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3851\/IMP1749","article-title":"Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient","volume":"16","author":"Boyd","year":"2011","journal-title":"Antivir. Ther."},{"issue":"2","key":"10.1016\/j.jcv.2017.04.012_bib0060","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3851\/IMP1748","article-title":"Transmission of integrase strand-transfer inhibitor multidrug-resistant HIV-1: case report and response to raltegravir-containing antiretroviral therapy","volume":"16","author":"Young","year":"2011","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.jcv.2017.04.012_bib0065","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/jac\/dkv284","article-title":"Transmitted drug resistance of HIV-1 strains among individuals attending voluntary counselling and testing in Taiwan","volume":"71","author":"Lai","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jcv.2017.04.012_bib0070","series-title":"NRES Algorithm \u2013 Requirements for REC review. Supplementary Notes on Research Not Requiring REC Review, Section 2","year":"2011"},{"issue":"9","key":"10.1016\/j.jcv.2017.04.012_bib0075","doi-asserted-by":"crossref","first-page":"e46181","DOI":"10.1371\/journal.pone.0046181","article-title":"Prolonged and substantial discordance in prevalence of raltegravir-resistant HIV-1 in plasma versus PBMC samples revealed by 454 \u201cdeep\u201d sequencing","volume":"7","author":"Lee","year":"2012","journal-title":"PLoS ONE"},{"issue":"6","key":"10.1016\/j.jcv.2017.04.012_bib0080","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1128\/JCM.06689-11","article-title":"Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool","volume":"50","author":"Woods","year":"2012","journal-title":"J. Clin. Microbiol."},{"issue":"Suppl","key":"10.1016\/j.jcv.2017.04.012_bib0085","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1086\/505356","article-title":"Rationale and uses of a public HIV drug-resistance database","volume":"194","author":"Shafer","year":"2006","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jcv.2017.04.012_bib0090","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jviromet.2015.02.016","article-title":"Development of an avidity assay for detection of recent HIV infections","volume":"217","author":"Shepherd","year":"2015","journal-title":"J. Virol. Methods"},{"issue":"3","key":"10.1016\/j.jcv.2017.04.012_bib0095","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1086\/427192","article-title":"Predictors of HIV drug-resistance mutations in a large antiretroviral-na\u00efve cohort initiating triple antiretroviral therapy","volume":"191","author":"Harrigan","year":"2005","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jcv.2017.04.012_bib0100","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.jcv.2015.07.030","article-title":"Re-emergence of HIV in the PWID population of Glasgow","volume":"70","author":"Jackson","year":"2015","journal-title":"J. Clin. Virol."},{"issue":"1","key":"10.1016\/j.jcv.2017.04.012_bib0105","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.antiviral.2009.11.004","article-title":"Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy","volume":"85","author":"McColl","year":"2010","journal-title":"Antivir. Res."},{"issue":"21","key":"10.1016\/j.jcv.2017.04.012_bib0110","doi-asserted-by":"crossref","first-page":"10366","DOI":"10.1128\/JVI.00470-08","article-title":"Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors","volume":"82","author":"Goethals","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.jcv.2017.04.012_bib0115","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1742-4690-5-74","article-title":"Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors","volume":"5","author":"Rhee","year":"2008","journal-title":"Retrovirology"},{"issue":"9","key":"10.1016\/j.jcv.2017.04.012_bib0120","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/infdis\/jir025","article-title":"HIV-1 integrase inhibitor resistance and its clinical implications","volume":"203","author":"Blanco","year":"2011","journal-title":"J. Infect. Dis."},{"issue":"10","key":"10.1016\/j.jcv.2017.04.012_bib0125","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1128\/AAC.00397-09","article-title":"Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors","volume":"53","author":"Low","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.jcv.2017.04.012_bib0130","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/QAI.0b013e3182237f74","article-title":"Effect of mutations at position E138 in HIV-1 reverse transcriptase on phenotypic susceptibility and virologic response to etravirine","volume":"58","author":"Tambuyzer","year":"2011","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"1","key":"10.1016\/j.jcv.2017.04.012_bib0135","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/135965350901400114","article-title":"Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors","volume":"14","author":"Tambuyzer","year":"2009","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.jcv.2017.04.012_bib0140","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1186\/1471-2334-12-368","article-title":"HIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland","volume":"12","author":"Parczewski","year":"2012","journal-title":"BMC Infect. Dis."},{"issue":"1","key":"10.1016\/j.jcv.2017.04.012_bib0145","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3851\/IMP2780","article-title":"Lack of resistance to integrase inhibitors among antiretroviral-naive subjects with primary HIV-1 infection, 2007\u20132013","volume":"20","author":"Stekler","year":"2015","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.jcv.2017.04.012_bib0150","series-title":"ICAAC 2015","article-title":"Absence of integrase inhibitor resistant HIV-1 transmission in the California AIDS Healthcare Foundation Network","author":"Volpe","year":"2015"},{"issue":"11","key":"10.1016\/j.jcv.2017.04.012_bib0155","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1093\/jac\/dkq326","article-title":"Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors","volume":"65","author":"Ceccherini-Silberstein","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jcv.2017.04.012_bib0160","doi-asserted-by":"crossref","first-page":"11440","DOI":"10.1128\/JVI.01168-09","article-title":"Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways","volume":"83","author":"Fransen","year":"2009","journal-title":"J. Virol."},{"issue":"7","key":"10.1016\/j.jcv.2017.04.012_bib0165","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1093\/jac\/dkv048","article-title":"Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response","volume":"70","author":"Charpentier","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jcv.2017.04.012_bib0170","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1128\/JCM.43.1.406-413.2005","article-title":"Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis","volume":"43","author":"Palmer","year":"2005","journal-title":"J. Clin. Microbiol."}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653217301233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653217301233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T18:41:58Z","timestamp":1719168118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386653217301233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":34,"alternative-id":["S1386653217301233"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2017.04.012","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HIV-1 integrase inhibitor resistance among treatment na\u00efve patients in the West of Scotland","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcv.2017.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2017 Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}